Other Sexual Problems
Page updated Winter 2023.
Disclaimer: Medicine is an ever-changing science. We have been witnessing changes in diagnostic and therapeutic modalities and guidelines during last several years. We have used sources believe to be reliable for purpose of this website including AUA guidelines, EAU guidelines, NCCN guidelines, Campbell-Walsh-Wein Urology, UpToDate, Merck Manual, Lexi-Comp, FDA website, and other reputable sources. However, due to possibility of human error or changes in medicine, readers are required to confirm the information provided in this website with other sources. Readers are specially required to read all parts of the product information sheet included in the package of each drug they plan to take or administer and follow those instructions. Readers are also needed to follow instructions of FDA and other regulatory bodies and their own department in this regard. Authors can cite information provided in our textbooks or they need to cite the original sources. This website serves as a general framework. We and other users would adjust the approach per departments policies and patients situation. Forms can be used by other health care professionals.
Testosterone Deficiency
Diagnostic criteria
Low total testosterone levels (300 ng/dL)- on 2 occasions and Symptoms and/or signs of testosterone deficiency
Tests
Testosterone: Early morning- times 2
LH
Prolactin: If low/normal luteinizing hormone levels
Estradiol: If breast symptoms or gynecomastia
Hemoglobin and hematocrit
PSA: In men over 40 years of age
Testosterone Therapy
Indications:
Men with low testosterone levels
and clinical symptoms of hypogonadism
Absolute contraindications:
Prostate cancer
PSA > 4 ng/mL
Nodules/induration on digital rectal examination
Breast cancer
Polycythemia (hematocrit > 54%)
Relative contraindications:
Baseline hematocrit > 50%
Desire for fertility
Severe lower urinary tract symptoms
Other cautions:
Testosterone should not be given for 3-6 months after cardiovascular events.
Treatment Goal: To achieve a total testosterone level in the middle tertile of the normal reference range.
Intramuscular Testosterone Injections
Testosterone Cypionate
IM- 50- 200mg every 7 -14 days. Initial dose: 50-100 mg
Testosterone Enanthate
Same as above agent
Injection Site: Gluteal muscle or lateral upper thigh
Most Frequent Adverse Effects
Local site reactions
Abnormally elevated hemoglobin
Transdermal Testosterone Gel
Androgel 1%
Dose:50 to 100 mg daily to shoulders, and upper arms
Most Frequent Adverse Effects
Local site reactions
Transference
HCG Injection
Indications: Hypogonadotrophic hypogonadal patients with fertility issues
Dose:1,500-5,000 IU two to three times weekly (M/W/F) to a maximum of 10,000 IU/week administered intramuscularly or subcutaneously.
Anastrozole (Arimidex)
0.5- 1 mg PO, 3/week (M/W/F)
Clomiphene (Clomid)
Start with 25 mg PO, 3 times per week (M/W/F) and slowly titrate up to 50 mg once a day as needed.
Follow-up
Testosterone levels: 2 to 3 months after therapy is initiated and then every 6-12 months
PSA:Increased PSA level greater than 1.4 µg/L within 12-month period of testosterone treatment or PSA level greater than 4.0 µg/L need urologic evaluation
Hematocrit, hemoglobin: An increase in hematocrit to greater than 52-54% should lead to cessation of treatment
FSH Injection
Indication: Patients who are receiving HCG and would like to conceive
Reasoning: Induction of testosterone synthesis by hCG alone may lead to suppression of FSH
FSH Injection :75–150 IU, SC injection, 2–3 times/ wk
hMG Injection:75 IU , SC injection, 2–3 times / wk
Hematospermia
Step 1: UA, DRE, PSA, per indications
Step 2- Persistent hematospermia (>2 months) needs further workup. This includes:
Infectious workup (urine culture, GC urethritis, non- GC urethritis, TB) if indicated
Semen analysis- may be considered
Coagulation studies
TRUS or MRI
Cystoscopy
Seminal vesicle endoscopy- has been considered by some urologists.
Premature Ejaculation
Topical Therapies
EMLA Cream (Lidocaine 2.5%/prilocaine 2.5%):20 to 30 minutes pre-intercourse
Selective Serotonin Reuptake Inhibitor
Fluoxetine (Prozac): 20-40 mg/day
Paroxetine (Paxil):10, 20, 40 mg/day or 20 mg 3 -4 h before sex
Sertraline (Zoloft): 50 to 200 mg/day or 50 mg 4 to 8 h before sex
Second Line Treatment
Tramadol: On demand: 20-100 mg
Notice- Also refer the patient to mental health professional with expertise in sexual health.
Concomitant Erectile Dysfunction
Erectile dysfunction should be treated first.
Delayed Ejaculation
Treat erectile dysfunction.
Address low testosterone if present.
Address medications that may contribute to delayed ejaculation.
Refer to mental health professional with expertise in sexual health.
Peyronie’s Disease
Oral Medications
Non-steroidal anti-inflammatory drugs
For pain management
Intralesional Injections
Collagenase (Xiaflex)
The only FDA-approved medication for Peyronie's disease
Disease should be stable.
May be used in patients with penile curvature >30° and <90°, and intact erectile function with or without the use of medications.
Steps:
1- Inducing penile erection: A single intracavernosal injection of 10 or 20 micrograms of Alprostadil
2- Identifying the target area
3- Waiting for penis to become flaccid
4- Injecting 0.58 mg XIAFLEX into the target plaque
5- Repeating the injection in 1 to 3 days
6- Performing penile modeling procedure 1 to 3 days after the second injection
Up to four treatment cycles may be administered.
Each treatment cycle may be repeated at approximately six-week intervals.
If the curvature deformity is less than 15 degrees after the first, second or third treatment cycle, treatment should be stopped.
Patient should not have sex or any other sexual activity between the first and second injections of a treatment cycle.
Patient should not have sex or have any other sexual activity for at least 4 weeks after the second injection..
Interferon α-2b
Verapamil
Surgery: Prerequisite:
Peyronie’s disease should be stable for at least three months (without pain or deformity deterioration)
Surgical options:
Tunica plication: If
Rigidity is adequate for coitus (with or without pharmacotherapy and/or vacuum device therapy)
There is adequate penile length
Curvature < 60°
There is no special deformities (hour-glass, hinge)
Plaque incision or excision and/or grafting: If
Rigidity is adequate for coitus (with or without pharmacotherapy and/or vacuum device therapy)
There is not adequate penile length
Curvature > 60º
There is special deformities (hour-glass, hinge)
Penile prosthesis : If
Rigidity is not adequate for coitus (with or without pharmacotherapy and/or vacuum device therapy)
Inflatable penile prosthesis is recommended in Peyronie's disease.
Congenital Penile Curvature
Nesbit surgery/ Other plication techniques
Priapism
Diagnosis
CBC- diff
Coagulation profile
Corporal aspiration and blood gas analysis
Ischemic priapism:
pO2 (mmHg) <30
pCO2 (mmHg) >60
pH < 7.25
Duplex ultrasound
To differentiate between ischemic and non-ischemic priapism as an alternative or adjunct to blood gas analysis.
Treatment of Ischemic Priapism
Post-treatment with combination of aspiration, irrigation, and alpha adrenergics erectile preserves in 70-92% of patients.
Supplies:
ABG Needle
25 Gauge Needle for Penile Block
16 Gauge Angiocatheter Needle X 2
Empty Syringes (10 cc and 60 cc)
Sterile Saline
Betadine
1% Lidocaine without Epinephrine
Phenylephrine Vials with concentration of 100- 500 mcg/mL
Cardiac Monitor
First step
Therapeutic aspiration (with or without irrigation) - Aspirate the corpora cavernosa until fresh red blood is obtained.
Intracavernosal phenylephrine injection
First, decompress by penile aspiration.
Dilute it with normal saline.
Concentration of 100 to 500 mcg/mL is needed.
Inject 1 mL every 3 to 5 minutes for approximately one hour.
Lower concentrations in smaller volumes is needed in children and patients with severe cardiovascular disease.
Blood pressure and electrocardiogram monitoring are needed in patients with high cardiovascular risk.
Second step
Corporoglanular shunt
Normal erectile function is preserved in 33.3- 50% of patients with distal shunt.
Options:
Winter: using large biopsy needle
Ebbehøj: using scalpel
Al-Ghorab: excising a piece of the tunica albuginea at the tip of the corpus cavernosum. Snake procedure may be added.
Third step; Proximal shunt. Options are:
Quackels
Grayhack
Forth step
Penile prosthesis
Consider it if :
Priapism episode is > 36 hours after onset.
Other interventions have failed.
Notice: A duration >36 hours is invariably associated with a degree of corporal fibrosis and erectile dysfunction
Treatment of Priapism in Sickle Cell Anemia
Follow above steps.
Oxygen
Intravenous hydration
Alkalization with bicarbonates
Blood exchange transfusions
Treatment of Recurrent Priapism
Medical treatment
Gonadotropin-releasing hormone (GnRH) agonists
Antiandrogens
Hormonal agents should not be used in pediatrics.
Intracavernosal self-injection
Phenylephrine
If patient fails or rejects systemic treatment.
Treatment of Non Ischemic Priapism
First step: Observation
Second step
Selected pudendal arteriogram and superselective arterial embolization
Autologous clot and absorbable gel are preferred to coils and chemicals, which are permanent.
Third step: Surgery